Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study

Author:

Ben-Ami Eytan1ORCID,Barysauskas Constance M.2,Solomon Sarah1,Tahlil Kadija1,Malley Rita1,Hohos Melissa1,Polson Kathleen1,Loucks Margaret1,Severgnini Mariano3,Patel Tara3,Cunningham Amy3,Rodig Scott J.34,Hodi F. Stephen35,Morgan Jeffrey A.1,Merriam Priscilla1,Wagner Andrew J.1,Shapiro Geoffrey I.67,George Suzanne1

Affiliation:

1. Center for Sarcoma and Bone Oncology; Dana-Farber Cancer Institute; Boston Massachusetts

2. Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute; Boston Massachusetts

3. Center for Immuno-oncology; Dana-Farber Cancer Institute; Boston Massachusetts

4. Department of Pathology; Brigham and Women's Hospital; Boston Massachusetts

5. Department of Medical Oncology; Dana-Farber Cancer Institute; Boston Massachusetts

6. Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA USA

7. Department of Medicine; Brigham and Women's Hospital and Harvard Medical School; Boston MA USA

Funder

National Cancer Institute

Catherine England Leiomyosarcoma Research Fund

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Cited by 174 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3